I keep telling myself, this thing is a buy under 8 bucks, but I fail to actually buy. And watching while that becomes true. 4th mouse gets the cheese?
IMHO, the market is pricing in hardly any chance of success for fostamatinib in Phase 3 and assigning very little value to the rest of RIGL's pipeline. We'll see if that ultimately proves to be a bit short-sighted. (I'm betting that it will though I haven't yet taken a position in RIGL again.)
Market Data 
Markets 
AI
